Drugs targeting PI3K/Akt/mTOR pathway were reported to cause hyperglycemia and hyperlipidemia, bone marrow suppression (particularly – anemia, thrombocytopenia, and neutropenia), stomatitis, hepatotoxicity, and pneumonitis [153]. This evidence concerns the gene AKT1 and anemia (phenotype).